Defects in the biosynthesis of N-and core 1 O-glycans may be found by isoelectric focusing (IEF) of plasma transferrin and apolipoprotein C-III (apoC-III). We hypothesized that IEF of transferrin and apoC-III in combination with SDS-PAGE of apoC-III may provide a classification for CDG patients.
Introduction
Congenital Disorders of Glycosylation (CDG) form a group of autosomal recessive metabolic disorders caused by defects in the biosynthesis of protein-linked glycans. Until now genetic defects mainly in the N-glycan biosynthesis have been classified as CDG. At present 18 genetically distinct types of CDG have been described; CDG-Ia through -Il and CDG-IIa through -IIf (Frank et al. 2004; Wu et al. 2004; Martinez-Duncker et al. 2005) . Isoelectric focusing of plasma transferrin (TIEF) is generally used as a screening for defects in the biosynthesis of N-linked glycans (Jaeken 2003) . The division of CDG into type I and type II is based on the location of the defect in the N-glycan biosynthetic pathway. CDG-I includes all defects in the early N-glycan pathway in the cytoplasm or in the endoplasmic reticulum (ER) and covers all enzymatic steps to the transfer of the glycan to the Isoelectric focusing of apolipoprotein C-III (apoC-III) has recently been described as a new screening assay for defects in the biosynthesis of core 1 O-glycans (Wopereis et al. 2003) . In mammals the most common form of O-glycosylation is the mucin type of O-glycosylation in which glycans are attached to the protein via a GalNAc residue. This mucin type O-glycosylation can be subdivided into eight core structures based on the second sugar(s) and/or sugar-linkage. The core 1 Oglycan, with Gal 1-3 GalNAc -(Ser/Thr) as the core, is the most common subtype and occurs on many membrane and secreted proteins, especially in mucus, brain and other neural tissue (van den Steen et al. 2000; Hounsell, Davies, and Renouf 1996; Finne 1975 (Topaz et al. 2004 ). Other inborn errors of metabolism that affect O-glycosylation are defects in proteoglycan biosynthesis (the progeroid variant of Ehlers Danlos syndrome (Okajima et al. 1999 ) and the multiple exostoses syndrome (Wuyts and Van Hul 2000) ) and defects in the biosynthesis of O-mannosyl glycans (Muscle-Eye-Brain disease (Yoshida et al. 2001) and Walker Warburg syndrome (Beltran Valero de Bernabe et al. 2002) ).
Nucleotide sugars, enzymes and transporters involved in the biosynthesis of glycans might be common to N-and O-glycans, explaining why some glycosylation defects will affect both the biosynthesis of N-and O-glycans. A congenital defect affecting both N-and O-glycans has been described previously in patients with CDG-IIe, who have a defect in subunit 7 of the conserved oligomeric Golgi complex (COG-7) (Wu et al. 2004) , in CDG-IIc (Lubke et al. 2001) , in a subgroup of patients with cutis laxa (Wopereis et al. 2004; Morava et al. 2005) and in a patient with an as yet unsolved defect (CDG-IIx (Wopereis et al. 2003) ).
In this study, we investigated nineteen patients with an unsolved CDG defect found in the selective screening with transferrin IEF. This patient group was divided into a CDG-Ix group and a CDG-IIx group based on the transferrin IEF profile. ApoC-III IEF and apoC-III SDS-PAGE made it possible to divide the CDG-IIx group into 6 biochemical subgroups. The strategy applied in this paper narrows down the options for the primary defect in the various subgroups especially for CDG-IIx patients. Table 2A . On the basis of the ratio of the transferrin isoforms two different TIEF profile types could be distinguished in patients with CDG type II. The 'asialo TIEF profile' is characterized by highly elevated levels of the asialo-and monosialotransferrin isoforms (see Figure 1 , lane 3). TIEF of plasma samples from patients 9,10, 13, and CDG-IId have this asialo TIEF profile.
The 'disialo TIEF profile' is characterized by normal or slightly elevated levels of asialo-and/or monosialotransferrin and increasingly higher levels of the disialo-and trisialo-transferrin isoforms (see Table 2B ). Out of the twelve CDG-IIx patients three had a normal apoC-III IEF profile (patients 8-10), while nine had an abnormal apoC-III IEF profile (patients 11-19) . The relative amounts of the apoC-III isoforms of patients 8-19 are summarized in Table 2B 
SDS-PAGE of apoC-III
SDS-PAGE of apoC-III was only performed in cases with abnormal profiles for apoC-III IEF.
Using SDS-PAGE, two bands of apoC-III could be distinguished; a major band containing apoC-III 1 and apoC-III 2 and a minor apoC-III 0 band. Two-dimensional electrophoresis (IEF and SDS-PAGE) has shown that the apoC-III 1 and apoC-III 2 bands co-migrate on SDS-PAGE (data not shown). Plasma from patients 14, 15 and the CDG-IIe patient showed an abnormal apoC-III SDS-PAGE pattern ( Figure 2A , lanes 4-6), while plasma from patients 11-13 and 16-19 had a normal apoC-III SDS-PAGE profile (not shown). The apoC-III 0 band of plasma from patients 14, 15 and the CDG-IIe patient migrated further into the gel than the apoC-III 0 band of the controls.
The samples from the patients with abnormal apoC-III SDS-PAGE profiles were sequentially treated with neuraminidase and O-glycosidase. Similar results were obtained for plasma from patients 14, 15 and the CDG-IIe patient. In Figure 2B the resulting SDS-PAGE profiles are shown of plasma from patient 15 (lanes 4-6) and from a control (lanes 1-3). After incubation of control plasma with neuraminidase, the sialic acid residues of apoC-III 2 and apoC-III 1 were cleaved off and apoC-III 0 with the Gal 1-3GalNAc glycan remained (see Figure 2B , lane 2). After neuraminidase treatment of plasma of patient 15, the lower band composed of apoC-III 2 and apoC-III 1 disappeared and a new band was visible at the position of apoC-III 0 with the Gal 1-3GalNAc glycan (see Figure 2B , lane 5).
Clearly, a second band is visible on top of the Gal 1-3GalNAc glycan, indicating a lower molecular mass.
After incubation of desialylated control plasma and of desialylated plasma of patient 15 with O-glycosidase, the Gal 1-3GalNAc glycan of apoC-III 0 was cleaved off and the protein part of apoC-III remained (see Figure 2B , lanes 3 and 6). This deglycosylated apoC-III band appears at the same
Discussion
In this study, we classified nineteen patients with unsolved CDG into seven biochemically distinct patient groups based on transferrin IEF, apoC-III IEF and apoC-III SDS-PAGE. A previous attempt to classify CDG-IIx cases was performed by Mills et al. by glycan analysis (Mills et al. 2003) . Clinically, the twelve CDG-IIx patients have a phenotype with widely variable clinical features as central nervous system involvement, hepatic dysfunction or congenital malformations (see Table 1 ). It was not possible to make a classification on basis of the clinical symptoms. For the robustness of our methodology it is encouraging that in biochemical group 6, three out of the four ). These three patients may share the same primary defect. The observed cutis laxa has not been described in other CDG subtypes so far.
In conclusion, the combination of the transferrin IEF, apoC-III IEF and apoC-III SDS-PAGE allowed us to subdivide the CDG type II patient group into six biochemically distinct groups. This subdivision narrows down the options for the position of the primary defect, with a limited number of theoretical possibilities for each individual patient. Table 1 .
Patients 17-19 have been described in more detail by Morava et al. ).
Polymorphisms of transferrin and of apoC-III were excluded by incubation of the samples with neuraminidase to remove the negatively charged sialic acid residues. After neuraminidase treatment, all transferrin and apoC-III isoforms migrated at the asialo position on IEF, indicating that changes in sialic acid content had been responsible for the abnormal profiles. All secondary causes for glycosylation abnormalities such as galactosemia, fructosemia, alcohol abuse and hemolytic uremic syndrome were excluded by appropriate measures. The IEF profiles of TBG, another N-glycosylated protein, were also abnormal in the nineteen patients (data not shown). This indicates that the defect is not restricted to the N-glycans of transferrin and affects the glycosylation of other N-glycosylated plasma proteins as well.
In addition, plasma samples from patients with established CDG subtypes were studied (CDGIa, n=8; CDG-Ib, n=1; CDG-Ic, n=8; CDG-Ie (Imbach et al. 2000b ), n=1, CDG-If (Schenk et al. 2001 ), n=1; CDG-IIa, n=1 (Jaeken et al. 1994) ; CDG-IId, n=1 (Peters et al. 2002) ; CDG-IIe, n=1 (Wu et al. 2004, P2) ).
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Samples and sample preparation Blood samples were obtained from children with unsolved CDG with informed parental consent. Plasma was prepared by centrifugation and stored immediately at -80 °C until required for analysis.
Transferrin and apolipoprotein C-III (apoC-III) isoelectric focusing (IEF)
Transferrin IEF was carried out essentially as described by van Eijk and van Noort (van Eijk and van Noort 1992) . Plasma samples were incubated for 30 minutes with a solution of 20 mM ferric citrate and 0.5 mM sodium hydrogen carbonate in a ratio of 10:3 (plasma to solution) to saturate the transferrin with iron. The iron-saturated plasma was diluted 5 times with water and applied to a hydrated immobiline gel (pH 4-7) on an Ultraphore system (Amersham Pharmacia Biotech).
Transferrin isoforms were detected after immunofixation with rabbit anti-human transferrin antibody (Dako, Glostrup, Denmark) and Coomassie blue staining. The relative amounts of the transferrin isoforms were determined by scanning the stained gel using an Image Master Labscan, Ver. 3.00 (Amersham Pharmacia Biotech) and quantified using Image Master 1D gel analysis, Ver. 4.10, software (Amersham Pharmacia Biotech).
IEF of apoC-III was carried out as described by Wopereis et al. (Wopereis et al. 2003) . A dry IEF Phastgel was hydrated in a solution of 8 M urea and 60 mL/L Pharmalyte pH 4.2 -4.9 and Ampholine pH 3.5 -5.0 (Amersham Pharmacia Biotech) in a ratio of 2:1. Plasma samples were diluted ten-fold with saline and applied to the hydrated gel on a Phastsystem. After IEF, the isoforms of apoC-III were detected by Western blotting using rabbit anti-human apoC-III antibody (ANAWA Biomedical Services & Products), and secondary goat anti-rabbit horseradish peroxidase-coupled antibody and visualized by electrochemiluminescence. The relative amounts of the apoC-III isoforms were determined by densitometry as described above.
SDS-PAGE of apoC-III
Plasma samples used for SDS-PAGE of apoC-III were diluted ten-fold with freshly made sample buffer (10 mM Tris/HCl pH 8.0, 1 mM EDTA, 2.5% SDS, 2% DTT and 0.01% bromophenol 14 blue). The diluted samples were heated at 100 °C for 5 minutes and applied to a 'Phastgel high density' on a Phastsystem with a separation time of 300 volthours at the standard running conditions for 'Phastgel high density'. After SDS-PAGE the apoC-III variants were detected by Western blotting using rabbit anti-human apoC-III antibody and secondary goat anti-rabbit horseradish peroxidasecoupled antibody and visualized by electrochemiluminescence.
Neuraminidase and O-glycosidase treatment
Negatively charged terminal sialic acid residues were removed from N-and O-linked glycans using neuraminidase. Neuraminidase (cat. no. 107590; Boehringer Mannheim; 1 g/L in 0.1 M Tris, pH 7.0) and human plasma samples were incubated in a ratio of 2:1 overnight at room temperature.
O-glycosidase can remove the unsubstituted Gal 1-3GalNAc unit from core 1 O-glycans. For that purpose O-glycosidase (cat. no. 1347101; Roche Applied Science; 0.5 mU/µL) and human plasma samples pretreated with neuraminidase, were incubated in a ratio of 1:1 overnight at 37 °C. 
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